Spotlight Growth
No Result
View All Result
Monday, July 4, 2022
  • Login
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

F-star Therapeutics (NASDAQ: FSTX) to be Acquired by Wholly-Owned Subsidiary of Sino Biopharm for $161 Million

by admin
June 23, 2022
in Bio/Med/Pharma
0
F-star Therapeutics NASDAQ FSTX Sino Biopharma invoX Takeover Spotlight Growth

F-star Therapeutics NASDAQ FSTX Sino Biopharma invoX Takeover Spotlight Growth

F-star Therapeutics, Inc. (NASDAQ: FSTX) operates as a clinical-stage biopharmaceutical company, which is focused on the research, development, and commercialization of immunotherapies to treat different types of cancers. Shares of the biopharma company are rallying 58% through early trading on Thursday, June 23, 2022. Over the past three months, F-star Therapeutics has seen average daily volume of 139,210 shares. However, volume of 5.7 million shares or dollar volume of around $36.37 million, has already exchanged hands through early trading.

Shares of F-star Therapeutics are gaining after the company announced it has entered into a definitive agreement to be acquired by invoX Pharma, a wholly-owned subsidiary of Sino Biopharmaceutical Limited. Under the terms of the agreement, invoX will acquire all the outstanding shares of F-star at a price per share of $7.12. This gives the takeover transaction an aggregate value of $161 million. The proposed transaction has been approved by the board of directors of both companies and the deal is estimated to close during the second half of 2022.

The Sino Biopharm subsidiary will gain access to F-star Therapeutics’ proprietary technology, which uses tetravalent (2+2) bispecific antibodies that are able to target two different antigens at the same time. F-star currently has four drug candidate programs that are undergoing clinical processing. The company also is said to have several undisclosed programs under development.

The four clinical programs that F-star is currently operating are FS118, FS222, FS120, and SB 11285:

“FS118: Rescuing CPI treatment failures & Improving outcomes in CPI naïve
A dual checkpoint inhibitor targeting PD-L1 and LAG-3. Phase 2 PoC trial underway in head & neck PD-1 acquired resistance patients as well as in CPI-naïve NSCLC & DLBCL.

FS222: Improving outcomes in PD-L1 low tumors
A CD137 (4-1BB) stimulator and PD-L1 inhibitor, with superior potency seen in pre-clinical activity. Phase 1 trial underway.

FS120: Improving CPI and chemotherapy outcomes
A conditional OX40/CD137 (4-1BB) dual agonist, with broad potential for combination. Phase 1 trial underway.

SB 11285: Improving CPI outcomes
A second generation STING agonist with Phase 1 monotherapy and PD-L1 (atezolizumab) combination trial underway.”

Eliot Forster, Chief Executive Officer of F-star said: “We believe our tetravalent bispecifics offer the best approach to tackle hard-to-treat cancers and other serious diseases, with the ambition to deliver longer and improved lives for patients. Today’s announcement is good news for F-star, for our shareholders and, of course, for patients. This transaction enables greater and longer-term opportunities to develop the F-star platform and accelerate delivery of our novel medicines as we work together towards a future free from cancer and other serious diseases. I’d like to thank the fantastic team at F-star as well as our partners for all their hard work, support and dedication and I’m delighted to share this exciting development.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

Tags: acquisitionbiopharmabiopharmaceuticalsbiotechcancer stocksclinical trialscommon stockday tradingemerging growthF-star TherapeuticsFSTXFSTX stockinvestinginvesting newsinvestmentmedicalMergermicrocap stocksNASDAQnewsoncologypharmaceuticalspublic companysalesSino Biopharmasmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stocksstock marketstock market newsstocksstocks to watchtechTechnologytechnology stockstradingtreatmentwebull wallstreetbets
Plugin Install : Widget Tab Post needs JNews - View Counter to be installed
  • Trending
  • Comments
  • Latest
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

November 22, 2021
Alfi NASDAQ ALF Ridesharing Tablet Rollout Spotlight Growth

Alfi, Inc. (NASDAQ: ALF) Climbs 51% After Entering Into Agreement with Miami-Based Fulfillment & Distribution Center For its Ridesharing Digital Tablet Rollout

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
Emergent Health OTC EMGE LOI Fusion Specialty Pharmacy Spotlight Growth

Emergent Health Corp. (OTC Pink: EMGE) Announces LOI to Acquire Fusion Specialty Pharmacy

June 29, 2022
Decibel Therapeutics NASDAQ DBTX Interim Data Phase 1b DB 020 Spotlight Growth

Decibel Therapeutics (NASDAQ: DBTX) Shares Positive Interim Data of its Ongoing Phase 1b Trial of DB-020

June 28, 2022
Ayurcann CSE AYUR OTCQB AYURF July Product Rollout Canada Spotlight Growth

Ayurcann (CSE: AYUR) (OTCQB: AYURF) Prepares for July New Product Rollout as Distribution Expansion Continues Across Canada

June 27, 2022
NeuroSense Therapeutics NASDAQ NRSN Stage III ALS Biomarker Study Spotlight Growth

NeuroSense Therapeutics (NASDAQ: NRSN) Details PrimeC’s Positive Results from Stage III ALS Biomarker Study

June 27, 2022

Recent News

Emergent Health OTC EMGE LOI Fusion Specialty Pharmacy Spotlight Growth

Emergent Health Corp. (OTC Pink: EMGE) Announces LOI to Acquire Fusion Specialty Pharmacy

June 29, 2022
Decibel Therapeutics NASDAQ DBTX Interim Data Phase 1b DB 020 Spotlight Growth

Decibel Therapeutics (NASDAQ: DBTX) Shares Positive Interim Data of its Ongoing Phase 1b Trial of DB-020

June 28, 2022

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us
Spotlight Growth

Copyright © 2021 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2021 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested